Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Cure Diabetes by Injection of Micro Pancreas Cell Therapy

Descrizione del progetto

Nuovo micro-organo per ripristinare la produzione naturale di insulina e regolare i livelli glicemici

La somministrazione permanente di insulina è l’unico approccio terapeutico per i pazienti diabetici destinato a evitare le gravi complicazioni, spesso potenzialmente letali, di questa malattia. Tuttavia, l’esigenza di iniezioni giornaliere, il monitoraggio costante della glicemia e i vincoli alimentari rappresentano un disagio notevole nella vita quotidiana dei pazienti. Il progetto Micro Pancreas, finanziato dall’UE, sta sviluppando un rivoluzionario micro-organo rigenerativo impiantabile sotto la cute per ripristinare la produzione naturale di insulina e per regolare i livelli glicemici. Il micro-pancreas è composto da un substrato 3D costruito a partire da isole pancreatiche umane, riducendo al minimo in tal modo la risposta immunitaria nei pazienti e migliorando la vitalità e l’attività delle isole.

Obiettivo

Diabetes is a constantly growing concern in Europe and worldwide. Patients with Diabetes suffer from lack of insulin production. Without it, glucose remains in the blood and causes significant complications that can be both short term -seizures and fainting that could result in coma or even death, and long-term - stroke, heart disease, blindness, kidney failure and limb amputation. Betalin is developing a biologic cure to Diabetes: the Micro Pancreas that after implantation under the skin (by injection) restores natural insulin production and blood glucose regulation. Micro Pancreas is a revolutionary regenerative micro-organ, based on cell therapy comprising a proprietary organ derived 3D scaffold – Micro-Organ Matrix (MOM), isolated human pancreatic islets from donors and MSCs, which reduce the risk of immune response in patients and improve the islet viability and function. Micro Pancreas eliminates insulin dependency in diabetes patients, removing the need for daily injections and injections correlated with meals, constant blood glucose monitoring and dietary constraints.
Instead, patients get a biological implant by injection of Micro Pancreas, that generates insulin naturally in response to glucose, improving considerably daily life of patients with diabetes, including children with Type 1 Diabetes and moreover, preventing the long-term complications caused by the disease.
Following successful feasibility studies conducted thanks to the European Commission (EC) through SME Instrument Phase 1, a growing market was identified for Micro Pancreas, due to the increasing prevalence of diabetes worldwide. Total market value is expected to more than double from $6.6B in 2013, reaching a value of ~$13.6B by 2023 in drug and treatment sales, with a CAGR of 7.6%. Betalin's project will help ease the economic burden of diabetes in National Health Services while positioning itself as a leading company in the treatment of Diabetes worldwide.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

SME-2 - SME instrument phase 2

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) H2020-EIC-SMEInst-2018-2020

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

BETALIN THERAPEUTICS LTD
Contributo netto dell'UE
€ 2 288 125,00
Indirizzo
3 MENACHEM BEGIN
5268101 Ramat Gam
Israele
PMI
Sì
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 3 503 750,00

Partecipanti (1)